Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul 5;14(7):e26593.
doi: 10.7759/cureus.26593. eCollection 2022 Jul.

Ulerythema Ophryogenes in a Saudi Male: A Case Report

Nouf Algharbi  1 , Yara Jazzar  2   3 , Asem Shadid  4 , Asem Almesfer  4
Affiliations
Case Reports

Ulerythema Ophryogenes in a Saudi Male: A Case Report

Nouf Algharbi et al. Cureus. .

Abstract

Ulerythema ophryogenes (UO) or keratosis pilaris rubra atrophicans faciei is a disorder of keratinization that primarily affects the face. The inflammatory process in UO may eventually result in alopecia. The incidence of this disorder is still unknown. We present a case of UO in a 28-year-old male, the first of its kind in Saudi Arabia.

Keywords: keratosis pilaris; keratosis pilaris rubra atrophicans faciei; perifollicular erythema; sos1 mutation; ulerythema ophryogenes.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Prominent telangiectasia and macular erythema sparing the nasolabial folds on the right side of the face.
Figure 2
Figure 2. Prominent telangiectasia and macular erythema sparing the nasolabial folds on the left side of the face
Figure 3
Figure 3. Multiple well-defined red to brown papules are present over the forehead. Eyebrows show areas of alopecia as well as well-defined confluent follicular erythematous papules.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ulerythema: Practice Essentials, Pathophysiology, Etiology. [ Jun; 2022 ];Janniger CK. https://emedicine.medscape.com/article/1118415-overview?utm_medium=email... 2022
    1. Ulerythema ophryogenes with multiple congenital anomalies. Burnett JW, Schwartz MF, Berberian BJ. J Am Acad Dermatol. 1988;18:437–440. - PubMed
    1. Rubinstein--Taybi syndrome and ulerythema ophryogenes in a 9-year-old boy. Gómez Centeno P, Rosón E, Peteiro C, Mercedes Pereiro M, Toribio J. Pediatr Dermatol. 1999;16:134–136. - PubMed
    1. Ulerythema ophryogenes, a rarely reported cutaneous manifestation of noonan syndrome: case report and review of the literature. Li K, Ann Thomas M, Haber RM. J Cutan Med Surg. 2013;17:212–218. - PubMed
    1. Ulerythema ophryogenes: updates and insights. Morton CM, Bhate C, Janniger CK, Schwartz RA. https://pubmed.ncbi.nlm.nih.gov/24605344/ Cutis. 2014;93:83–87. - PubMed

Publication types

LinkOut - more resources